Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2010 June;62(3) > Minerva Ginecologica 2010 June;62(3):237-52

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GINECOLOGICA

A Journal on Obstetrics and Gynecology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEWS  REPRODUCTIVE MEDICINE - PART II


Minerva Ginecologica 2010 June;62(3):237-52

language: English

Preservation of ovarian function

Fabbri R., Pasquinelli G., Magnani V., Tamburini F., Battaglia C., Paradisi R., Keane D., Venturoli S.

1 Human Reproductive Medicine Unit, Obstetrics and Gynaecology, S.Orsola Hospital, Bologna, Italy;
2 Clinical Pathology Section, Experimental Pathology, S. Orsola Hospital, Bologna, Italy;
3 Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, Rotunda Hospital, Dublin, Ireland


PDF  


In the last years, advances in diagnosis and new treatments of cancer patient have increased the life expectancy of children, adolescent and women with cancer. Unfortunately, the ovaries are very sensitive to chemio-radiotherapy that may induce the loss of ovarian function and fertility with consequent premature ovarian failure. The different cryopreservation options available for fertility preservation in cancer patients are embryo cryopreservation, oocyte cryopreservation and ovarian tissue cryopreservation. The choice depends on different parameters: the type and timing of cancer treatment, the type of disease, the patient’s age. The advances in reproductive technology have made fertility preservation a real possibility for patients whether they are girls or young women whose gonadal function is threatened by natural premature menopause, or by cancer therapy or surgical sterilisation.

top of page

Publication History

Cite this article as

Corresponding author e-mail

raffaella.fabbri@unibo.it